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INTRODUCTION 
 
Epilepsy is recognized as the commonest serious neurological 
disorder in the world. Women with epilepsy (WWE) experience several 
gender-related physical and social problems. They constitute high obstetric 
risk because of reduced fertility, risk of seizures during pregnancy, and 
complications of pregnancy. Hormonal and other factors can alter the 
pharmacokinetics of antiepileptic drugs (AED) during pregnancy and 
puerperium. Antenatal exposure to AEDs, particularly at higher dosage and 
in polytherapy, increases the risk of fetal malformation. Recent reports raise 
the possibility of selective developmental language deficits and 
neurocognitive deficits with antenatal exposure to AEDs. 
 
Epilepsy and antiepileptic therapy therefore affects both maternal and 
fetal well being. Seizure type as well as AEDs used have an effect on the 
course and outcome of pregnancy. Conversely, pregnancy affects seizure 
control and the pharmacokinetics of AEDs. The management of a woman 
with epilepsy during her pregnancy thus presents a major therapeutic 
challenge to the treating physician. 
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AIMS OF THE STUDY 
 
This study analyzes the incidence of various maternal & foetal 
outcomes occurring in pregnant women with epilepsy. 
 
Maternal outcomes 
1. Primary outcomes     :   abortions, IUD, live births, maternal mortality 
2. Secondary outcomes :    Mode of delivery 
Seizures during pregnancy and delivery 
 
Foetal outcomes 
1. Primary outcome       :  Congenital malformations 
2. Secondary outcomes :   Infant mortality, growth retardation 
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REVIEW OF LITERATURE 
 
Epilepsy is a common neurological disorder with a prevalence rate of 
approximately 0.5% in most communities.  It is estimated that there are over 
2.5 million women with epilepsy (WWE) in India, with up to 52% of them 
being in the reproductive age group. People with epilepsy, especially 
women, experience tremendous social stigma and alienation in life2. 
Neurologists, Physicians and obstetricians are increasingly faced with WWE 
during pregnancy, but are not adequately informed about their optimal 
management. 
Several important aspects need to be attended to, while managing 
pregnancy in WWE: Pregnancy influences the natural history of epilepsy 
and seizure frequency is likely to change; the bioavailability of antiepileptic 
drugs (AEDs) may change considerably owing to alterations in its 
pharmacodynamics and kinetics. Both epilepsy as well as AED therapy may 
have an impact on outcome and mode of termination of pregnancy. Most 
importantly AEDs are potentially teratogenic and hence may increase the 
risk of fetal malformations.Psychomotor retardation in the offspring is also a 
concern in women with epilepsy1. 
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EFFECT OF PREGNANCY ON EPILEPSY 
 
Hormonal aspects of epilepsy 
Experimental and clinical studies have shown that seizures are 
influenced by the female sex hormones estrogen and progesterone. In 
general, estrogen lowers the seizure threshold and progesterone elevates it. 
In most experimental animal models, estrogen lowers the threshold for 
seizures induced by electroshock, kindling, pentylenetetrazol, and other 
agents. Progesterone, on the other hand, reduces spontaneous and induced 
epileptiform discharges. Similar observations have been made in human 
beings also7. 
Effect of pregnancy on seizure frequency 
Pregnancy has a variable effect on seizure frequency. Seizure 
frequency may remain unchanged or decreases in two-third of WWE, 
whereas it may increase in others. Seizure frequency may also vary between 
pregnancies in the same woman. There can be diverse patterns of seizure 
frequency during pregnancy. WWE may have a stable pattern with seizure 
frequency remaining more, less, or unchanged throughout the entire period 
of pregnancy. Others may have an unstable pattern wherein the seizure 
frequency may vary widely and often unpredictably during different months 
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of pregnancy. In a recent study it was observed that nearly 61% patients had 
a stable pattern and 39% women had an unstable pattern7,10. 
In most studies, seizure frequency has been observed to increase in 
about one third of the patients. While rare isolated seizures carry uncertain 
risks, uncontrolled convulsive seizures place both mother and baby at risk, 
increased risk of injury or other complications of seizures in the mother, and 
increased risk of bradycardia, placental abruption, premature labor, 
intracranial hemorrhage, or even fetal death in the baby; this risk is 
particularly high if seizures progress to status epilepticus. Effects of 
nonconvulsive seizures on developing fetuses are not well documented. 
Diverse mechanisms have been put forward to explain the change in 
seizure frequency during pregnancy. Apart from the reproductive hormones, 
several other factors such as noncompliance and decrease in blood levels of 
free form of AED, influence seizures during pregnancy. Increased stress and 
sleep deprivation may contribute. Physiologic changes of pregnancy that 
may alter seizure threshold include increase in sex hormone levels and 
sodium and water retention. Altered physiology of pregnancy also can 
change previously stable AED levels owing to changes in absorption (either 
through gastric motility changes or nausea and vomiting), changes in volume 
of distribution, alterations in protein binding, and increase in hepatic 
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metabolism. Providers also must be sensitive to the possibility that lower 
AED levels reflect noncompliance with medication due to fear of teratogenic 
effects1. 
Another factor to be noted is that women who have poorly controlled 
seizures even before pregnancy, have a higher incidence of seizures during 
pregnancy23. 
AED levels should be monitored more closely than usual during 
pregnancy. Pharmacokinetic changes demand monitoring of free levels of 
highly protein bound AEDs to avoid confusion with increased seizures      
(or symptoms of toxicity) despite therapeutic total serum drug levels. 
 
 
 
 
 
 
 
 
 
 7
EFFECT OF EPILEPSY ON PREGNANCY 
 
Infertility 
It is generally considered that women with epilepsy have reduced 
fertility rate.This is explained by a number of reasons usually acting in 
concert in each individual case4. 
The proportion of women who get married and the age at marriage 
can influence the fertility rate. The demographic, social, economic, and 
medical factors that influence marriage in women with epilepsy need further 
examination2. 
Polycystic ovarian disease (PCOD), an important cause for infertility, 
may occur in approximately 10% of women in the community. It should be 
distinguished from polycystic ovaries that may be seen in as much as 20% of 
women in the community. The European-American consensus workshop 
requires two of the three criteria (oligo/anovulaton, clinical, or biochemical 
signs of hyperandrogenism and polycystic ovaries) to be present in order to 
diagnose PCOD. It appears that women with epilepsy have an increased 
tendency for PCOD. 
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Use of sodium valproate had been shown to correlate with the 
presence of PCOD, which reverses when valproate is substituted by another 
AED9. A recent consensus report has recommended that if a reproductive 
endocrine disorder is found, AED treatment should be reviewed to ensure 
that it is correct for the particular seizure type and that it is not contributing 
to the endocrine problem. The possible benefits of a change in treatment 
must be balanced against seizure control and the cumulative side effect of 
alternative agents5. 
Complications of pregnancy 
It is uncertain whether women with epilepsy have more complications 
of pregnancy. Several studies have shown a higher frequency of the 
following complications. But these findings have not been validated by all 
studies. 
1)  Pre eclampsia 
2)  Eclampsia 
3)  Abruptio placenta 
4)  Spontaneous abortion 
Frequency of cesarean section may be increased for women with 
epilepsy, although most of them can have normal vaginal delivery. Uterine 
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inertia, seizures, and failure of progression of labor are usual causes of 
cesarian section .Frequency of induced labor is also higher28. 
Indications for cesarean section 
Elective cesarean section 
Poor control of seizures 
Intrapartum seizures 
Substantial neurological or mental retardation 
Uterine inertia 
Failure of induction of labor 
Heavy sedation for patient 
Fetal asphyxia
 10
Effects of maternal seizures on the fetus 
 
Seizures, especially in late gestation and delivery,may adversely affect 
the fetus by causing autonomic, metabolic  and direct traumatic effects. 
A generalized seizure at term can cause transient fetal asphyxia 
secondary to maternal hypoxia and placental insufficiency. Fetal 
bradycardia, reduced variability, and decelerations indicating fetal distress 
are seen for approximately 15 min after grand mal seizure. 
Generalized seizures can also cause direct fetal trauma leading on to 
consequences like intracranial hemorrhage. 
There is no evidence that nonconvulsive seizure affects the fetus 
adversely13. 
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EFFECT OF EPILEPSY AND AED ON FOETUS 
 
Effects on fetal and neonatal anthropometric parameters 
Minor variations in anthropometric features have been observed in 
infants of mothers with epilepsy26. Low birth weight and reduced length and 
head circumference have been observed in certain studies. A recent study 
has shown that infants exposed to AEDs may have increased tendency for 
minor facial anthropometric variations when compared to normal babies. 
However, this variation was not correlated with any specific AED or with 
polytherapy compared with monotherapy5.
 
Physiological impairments that were noticed in the newborns include 
low Apgar score and failure to thrive. Babies born to mothers taking 
phenobarbitone may experience mild irritability owing to the withdrawal 
effect of phenobarbitone, but it is likely to disappear in a few days’ time. 
Rarely, withdrawal seizures have been noticed in exposed neonates6. 
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Malformations 
The risk of malformation in the baby is one of the major concerns for 
women with epilepsy. Deviations from normal development can be 
classified into major malformations and minor anomalies. 
Malformations refer to major abnormalities that require surgical 
intervention within the first year of life or are likely to result in significant 
impairment and disability, e.g., neural tube defects (NTDs), congenital heart 
disease, or cleft palate. Anomalies are minor deviations from normal 
development that may not cause significant impairment or disability, e.g., 
Hypertelorism, acral hypoplasia of nails. 
In 1964, Janz first drew attention to the possible teratogenic effects of 
AED’s.
 
Since then several fetal syndromes such as fetal hydantoin 
syndrome, fetal ethosuximide syndrome and fetal phenobarbitone syndrome 
have been described. The commonly observed malformations may affect 
cardiovascular system, gastrointestinal system, skeletal and connective 
tissues, and central nervous system.
 
It had been observed that the 
malformations observed with different AEDs share much in common and 
are often indistinguishable. Hence, they are often referred to as fetal AED 
syndromes24. 
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Phenytoin 
Phenytoin is the oldest nonsedative antiseizure drug, introduced in 
1938. 
Mechanism of action: Phenytoin is a diphenyl substituted hydantoin. 
It has major effects on several physiological systems. It alters sodium, 
potassium and calcium conductance , membrane potentials and the 
concentrations of amino acids and neurotransmitters norepinephrine, 
acetylcholine and GABA. 
Studies with neurons show that phenytoin blocks sustained high 
frequency repetitive firing of action potentials. It is a use dependant effect on 
sodium conductance, arising from preferential binding to and prolongation 
of the inactive state of the sodium channel. This effect is seen at 
therapeutically relevant concentrations. The drug also interacts with 
membrane lipids and this might promote stabilization of membranes36. 
Pharmacokinetics: Absorption is highly dependant on the formulation of 
the dosage form. Absorption from gastrointestinal tract is nearly complete 
though the time to peak values may range from three to twelve hours. 
Phenytoin is highly bound to plasma proteins. The half life of phenytoin 
varies from 12 to 36 hours, with an average of 24 hours for most patients. It 
may take 5 to 7 days to reach steady state blood levels after each dosage 
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change. Phenytoin is metabolized by the liver, at low blood levels 
metabolism follows first order kinetics. But as therapeutic levels are reached 
metabolism is saturable36. 
Therapeutic levels and dosage: The therapeutic plasma level of phenytoin 
for most patients is between 10 and 20µg/ml. When oral therapy is started it 
is common to begin most adults at a dose of 200 to 300mg/day. If seizures 
continue higher doses are usually necessary to achieve plasma levels in the 
upper therapeutic range. Because of its dose dependant kinetics some 
toxicity may occur with only small increments in dose. 
Drug interactions: They are primarily related to protein binding or to 
metabolism. Since phenytoin is 90% bound to plasma protein changes in 
protein levels will affect total drug levels. Phenytoin has been shown to 
induce microsomal enzymes responsible for the metabolism of a number of 
drugs. Other anti epileptic drugs notably phenobarbitone and carbamazepine 
decrease steady state concentrations of phenytoin through hepatic 
microsomal enzyme induction. On the other hand drugs like isoniazid inhibit 
the metabolism of phenytoin and increase drug levels. 
Adverse effects: Higher doses can cause several neurological manifestations  
like nystagmus, diplopia, ataxia and peripheral neuropathy. Gingival 
hyperplasia and hirsutism occur to some degree in most patients. Chronic 
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use also results in abnormalities in vitamin D metabolism and osteomalacia. 
Idiosyncratic reactions like skin rash and agranulocytosis may also be seen. 
Use of phenytoin in pregnant women is associated with increased 
risks of both minor and major malformations in the foetus. Phenytoin is 
particularly associated with an increased risk of cleft lip and palate as well as 
dysmorphic features such as nail and distal phalangeal hypoplasia and 
craniofacial abnormalities25 . 
Phenobarbitone 
Phenobarbitone is the oldest of the currently available anti epileptic 
drugs and is still widely used in India. Although it has long been considered 
one of the safest of the antiseizure agents, the use of other medications with 
less sedative effects has been urged. 
Mechanism of action: Phenobarbitone enhances inhibitory processes and 
diminishes excitatory transmission. It binds to an allosteric regulatory site on 
the GABA-benzodiazepine receptor, and it enhances the GABA receptor 
mediated current by prolonging the opening of chloride channels. It also 
blocks excitatory responses induced by glutamate, principally those 
mediated by the action of the AMPA receptor. At high concentrations 
phenobarbitone suppresses high frequency repetitive firing in neurons36. 
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Pharmacokinetics: Phenobarbitone has a slow oral absorption and a long 
plasma half life of 80 to 120 hours. Steady state concentrations are reached 
in two to three weeks and a single daily dose can be used for maintenance. 
Phenobarbitone is 20% plasma protein bound. It crosses the placenta and is 
secreted in milk, can produce effects on the foetus and the suckling infant. It 
is metabolized by the liver and excreted by the kidney. 
Therapeutic levels and dosage: Therapeutic levels inn most patients range 
from 10 to 40µg/ml. It is usually used in a dose of 60mg one to three times a 
day in adults. 
Clinical use: It is useful in the treatment of generalized tonic clonic 
seizures, though the drug is virtually tried for every seizure type especially 
when attacks are difficult to control. Its most well documented use is in 
febrile seizures. 
Drug interactions and toxicity: Barbiturates induce the metabolism of 
several drugs and reduce their effectiveness – warfarin, steroids, 
tolbutamide, theophylline. It also has interactions with other anti epileptic 
drugs. Valproate increases concentrations of phenobarbitone. 
Phenobarbitone has been associated with congenital heart defects, 
facial clefts, and a specific pattern of minor anomalies and dysmorphic 
features5. 
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Sodium valproate 
Sodium valproate, also used as the free acid, valproic acid, was found 
to have anti seizure activity when it was used as a solvent in search of other 
agents effective against seizures. Valproic acid is fully ionized at body ph, 
and for that reason the active form of the drug may be assumed to be the 
valproate ion regardless of whether valproic acid or a salt of the acid is 
administered . 
Mechanism of action: valproate is active against both pentylenetetrazol and 
maximal electroshock seizures. It blocks sustained high frequency repetitive 
firing of neurons at therapeutic concentrations. Valproate owes its broad 
spectrum of activity to more than one molecular mechanism. It prolong 
sodium channel inactivation. It augments release of inhibitory transmitter 
GABA, at higher concentrations it also inhibits GABA degradation. In 
addition it also has an ethosuximide like action, in that it suppresses calcium 
mediated ‘T’ current36. 
Pharmacokinetics: Valproate is well absorbed following an oral dose, with 
bioavailability greater than 80%. Peak blood levels are observed within two 
hours. The drug is also 90% bound to plasma proteins. Since valprote is both 
highly ionized as well as protein bound, its distribution is essentially 
confined to extracellular water, with a volume of distribution of 
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approximately 0.15l/kg. its half life varies from 9 to 18 hours. It is 
metabolized in the liver by oxidation and glucuronide conjugation and 
excreted in urine36. 
Therapeutic levels and dosage: dosages of 25 to 30mg/kg/day may be 
adequate in some patients, but others may require up to 60mg/kg. therapeutic 
levels of valproate range from 50 to 100µg/ml. 
Clinical use: Valproate has a very broad spectrum of action. It is a first line 
drug for GTCS, simple and complex partial seizures as well as absence 
seizures. Valproate is unique in its ability to control certain types of 
myoclonic seizures. A few patients with atonic attacks may also respond. 
Other uses of valproate include management of bipolar disorder and 
migraine prophylaxis. 
Drug interactions: Valproate inhibits the metabolism of several drugs, 
including phenobarbitone, phenytoin and carbamazepine leading to higher 
steady state concentrations of these agents. Valproate also displaces 
phenytoin from plasma proteins9. 
Toxicity: The most common dose related adverse effects of valproate are 
nausea, vomiting and other gastrointestinal complaints. A fine tremor is 
frequently seen at higher doses. Other reversible adverse effects include 
weight gain, increased appetite and hair loss. The idiosyncratic toxicity of 
 19
valproate is largely limited to hepatotoxicity which may be severe.   
Valproate in pregnancy has been associated with a 1–2% risk of neural tube 
defects. Some studies have suggested that daily doses of valproate greater 
than 1,000 mg/day carry a greater risk of spina bifida and other 
malformations possibly due to high peak serum concentrations of valproate. 
Three or four times daily treatment or slow-release preparations may 
minimize this risk by reducing peak plasma levels, although the UK 
pregnancy database has failed to show any benefit of a slow-release 
formulation. There is also an increased incidence of cardiovascular and 
urogenital malformations. Thus, although valproate is a very effective drug 
for women with generalized epilepsies, the risks and benefits should be 
carefully considered20 . 
Carbamazepine 
Chemically related to imipramine, carbamazepine is a tricyclic 
compound initially introduced for the treatment of trigeminal neuralgia. 
Mechanism of action: The mechanism of action appears to be similar to 
that of phenytoin. It blocks sodium channels at therapeutic concentrations 
and inhibits high frequency repetitive firing in neurons. It also acts 
presynaptically to decrease synaptic transmission. Carbamazepine also 
inhibits uptake and release of norepinephrine from brain synaptosomes . 
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Pharmacokinetics: The rate of absorption of carbamazepine varies widely 
in different patients. Peak levels are usually achieved 6 to 8 hours after 
administration. The drug is only 70% protein bound, no displacement of 
other drugs from protein binding sites has been observed. The drug also has 
the ability to induce microsomal enzymes. It induces its own metabolism 
and the half life decreases to about 20 hours in long term users. 
Therapeutic levels and dosage: In adults a daily dose of 1 to 2 grams is 
used. Therapeutic levels are usually between 4 to 8µg/ml. 
Clinical use: It is considered the drug of choice for partial seizures. It is also 
one of the first line drugs for GTCS. Other uses include trigeminal neuralgia 
and bipolar disorder36. 
Drug interactions: Drug interactions involving carbamazepine are almost 
entirely related to the drugs enzyme inducing properties. Induction of 
hepatic enzymes may cause a reduction in the steady state concentration of 
carbamezepine itself and an increased rate of metabolism of primidone, 
phenytoin, ethosuximide, valproate and clonazepam. No clinically 
significant protein binding interactions have been reported10. 
Toxicity: The most common dose related adverse effects are diplopia and 
ataxia. Hyponatremia and water intoxication have occasionally occurred. 
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Idiosyncratic blood dyscrasias like aplastic anemia and agranulocytosis  
have also been observed. Hepatic dysfunction is rarely seen. 
The risk of congenital malformations with carbamazepine 
monotherapy is similar to that of most other anti epileptic dugs. In one study, 
there was a 0.9% reported risk of neural tube defects in the offspring of 
mothers who took carbamazepine through pregnancy . There have also been 
reports of reduced head circumference at birth, developmental delay, and 
dysmorphic features . 
Lamotrigine 
The indications for the use of this drug are similar to those for use of 
valproate. The incidence of major malformations with this drug is lower than 
with valproate. The UK and Australian pregnancy databases currently 
suggest that the risk of fetal malformations with lamotrigine monotherapy is 
similar to that of carbamazepine. Persons on LTG may experience increase 
in seizure frequency during pregnancy because LTG is eliminated much 
faster than during non pregnant state17. 
There are not yet enough monotherapy pregnancies with any of the 
other newer AEDs to be able to accurately advise women, although a recent 
review of oxcarbazepine does not appear to show an increased risk or any 
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specific pattern of malformations. Both topiramate and zonisamideare 
teratogenic in animal studies40. 
AED’s and teratogenecity 
The report of 'foetal hydantoin syndrome' was first published in 
1960s. Since then many aspects of drug toxicity in the foetus have been 
reported, the salient points being that: 
a)   Infants of mothers with epilepsy are at greater risk of developing  
       congenital malformations than general population. 
b)  Foetal malformations among infants born to mothers with epilepsy 
      on AEDs during pregnancy are higher than among infants of 
                epileptic mothers not exposed to AEDs in-utero. 
c)   Mean serum AED level is higher in mothers of infants with 
                 malformation. 
  d)   Infants of mothers on polytherapy have higher rates of 
       malformations4. 
Major malformations are defined as defects of medical, surgical or 
cosmetic importance. This type of anomaly, which will seriously affect a 
child’s life, occurs in 2 to 3 percent of all liveborn children. Types of major 
malformations occurring most often in children of women with epilepsy are 
orofacial clefts, cardiac abnormalities and neural tube defects. The incidence 
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of minor physical defects in infants born to women with epilepsy is 
approximately 15 percent. Features such as hypertelorism, epicanthal folds, 
shallow philtrum, distal digital hypoplasia, and simian creases are examples 
of minor congenital malformations.  Although the incidence is reported as 2 
to 3 times greater in women with epilepsy, these may be present in infants 
whose mothers use other types of medication or have excessive alcohol 
intake during pregnancy. These anomalies do not cause any serious 
problems and are primarily of cosmetic concern3. 
Studies suggest that the risk of significant fetal malformation is 
approximately 3% if one AED is taken (slightly above the background risk) 
and up to 17 % if two or more AEDs are taken . Most major malformations 
develop at an early stage in pregnancy, often before the woman knows she is 
pregnant2. AED exposure in the later stages of pregnancy may still lead to 
minor morphological abnormalities or specific learning difficulties 
(particularly in association with valproate sodium therapy). The mechanisms 
whereby AEDs are teratogenic have not been definitely established. Recent 
pregnancy databases have suggested that valproate is significantly more 
teratogenic than carbamazepine, and the combination of valproate sodium 
and lamotrigine is particularly teratogenic.In a recent study the rate of major 
congenital malformations was 2.4% in women with epilepsy not taking 
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AED's, 3.4% on monotherapy, 6.5% on polytherapy. In the same study 
monotherapy associated major malformations rate was 2.3% for 
carbamezipine, 2.1% for lamotrigine and 5.9% for sodium valproate. 
Valproic acid is the only AED for which a dose dependency has been 
confirmed in several studies, the increase in risk of major congenital 
malformations compared with other AED's is especially evident at doses 
above 800-1000 mg/day5. 
The extent of the causal relationship with AEDs has been questioned, 
and evidence has been put forward for maternal genetic factors influencing 
the development of minor abnormalities such as epicanthus and 
micrognathia. Larger prospective studies of women treated with 
monotherapy are necessary to resolve these issues1. 
Neurocognitive development and AED exposure in-utero 
Most babies born to women with epilepsy are normal. Recent reports 
suggest that these babies may have an increased risk of developmental delay 
or specific learning disabilities. Factors other than the maternal epilepsy that 
are thought to be important are IQ scores in the mother and AED 
polypharmacy (particularly exposure to phenobarbital in utero). Further 
studies are needed for validation of these reports16. 
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MANAGEMENT OF PREGNANCY IN EPILEPSY 
Preconceptional management 
Preconceptional evaluation is the most important phase in the 
management of epilepsy and pregnancy. Women with epilepsy need to have 
a neurological review at this stage, in order to ascertain the diagnosis and the 
need for continued treatment with AEDs. Several professional groups have 
examined this aspect in great detail and have come out with evidence based 
practice guidelines2,4. 
Most studies have shown that the risk of malformations in fetus is 
likely to be low with monotherapy, use of relatively lower dose, spacing of 
daily dose into multiple aliquots, and preconception use of folic acid. The 
controlled or extended release formulations of AEDs are likely to maintain a 
steady blood levels without much fluctuations. There is considerable 
variation in the risk of malformations with different AEDs even when used 
as monotherapy. Different AEDs carry different therapeutic efficacies 
against different seizure types. It may be possible to withdraw AED if the 
patient had remained seizure-free for more than 2 years. The general 
guidelines for AED withdrawal as for patients in remission are followed in 
WWE also. Persons with juvenile myoclonic epilepsy may have to continue 
therapy, even when they had been seizure-free for quite some time and the 
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EEG was normal. In the case of high-risk pregnancies (with family history 
of NTDs or previous pregnancies with birth defects), the option of an 
alternate AED needs to be discussed with the patients although the second 
AED may also carry the potential risk. There is much debate regarding the 
choice of AED for women with juvenile myoclonic epilepsy who are 
contemplating pregnancy. The risk and benefits of VPA vs LTG or TPM 
needs to be discussed with them so that the patients would be able to make 
an informed choice. High-dosage VPA and combination of VPA and LTG 
may be avoided, if possible, in preconception period and early pregnancy4. 
A universal recommendation for antenatal care includes prescription 
of 0.4 mg of folic acid daily19. The dosage of folic acid recommended for 
women with higher risk varies from 1–4 mg daily in several countries. 
Women in developing countries may be at higher risk of folic acid 
deficiency owing to dietary inadequacy, infections, or concomitant use of 
other drugs. In India, 5-mg tablets of folic acid are readily available. It is 
therefore recommended that all women planning pregnancy should receive 5 
mg daily of folic acid. The general protocol for preconception management 
of WWE that is followed in the Indian Registry of Epilepsy and Pregnancy 
(IREP)
 
is depicted2 . 
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Management of epilepsy during pregnancy 
Seizures tend to improve or remain unchanged in nearly two thirds of 
women with epilepsy. The risk of seizures is higher in the first trimester of 
pregnancy and around delivery time. The policy of the IREP is to avoid any 
change in AEDs once pregnancy had been confirmed. Nevertheless, in cases 
of polytherapy with multiple drugs, it may be possible to eliminate the third, 
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and occasionally the second, AED after retaining the AED(s) appropriate for 
the seizure. It is preferable to keep the total daily dose of VPA below 1000 
mg as higher doses have been implicated with an increased risk of NTD(18). 
Care should be taken to split the daily dose in to three or four divided 
aliquots in order to avoid high peak levels in the blood. It is important to 
ensure good compliance with AEDs throughout pregnancy in order to avoid 
relapse of seizures. The dosage may have to be increased in some patients in 
the third trimester, especially if the blood levels (preferably free drug levels) 
are low. The risk of seizure relapse around the time of delivery is three times 
more than during the rest of the pregnancy. The increased risk of seizure 
relapse is probably related to the lack of compliance, dehydration, prolonged 
fasting, or effect of concomitant medications. Care should be taken to avoid 
such provoking factors at the time of delivery. Status epilepticus can occur 
rarely during pregnancy (less than one percent). General guidelines for 
managing SE can be followed in such instances. The fetal outcome had been 
poor when it took a long time to control seizures2. 
Follow up in pregnancy 
The general schedule of antenatal check-up should be followed in all 
WWE. Folic acid supplementation should be initiated as soon as pregnancy 
is confirmed, if it had not been started in the preconception period2. 
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Monitoring for fetal malformations 
Monitoring for fetal malformations should be carried out towards the 
end of first trimester. Biochemical screening in the form of serum AFP 
levels as well as radiological screening using ultrasound is begun by about 
the    12th - 14th week of gestation. 
The first line screening procedure would be estimation of serum        
α-feto-protein (AFP), which tends to be elevated in cases of open NTD. 
Serum levels of AFP increase gradually during the first trimester and drop 
toward the fourth month of pregnancy. Hence, the levels should be 
correlated with the period of pregnancy preferably with conceptual age, 
calculated with the help of ultrasonography. A recent trend is to express the 
AFP level as multiples of medians for that period of pregnancy37. This 
makes interlaboratory comparisons easier. AFP levels could be elevated for 
other reasons such as twin pregnancy, placental hemorrhage, etc. If the AFP 
levels are abnormally elevated, the trend needs to be ascertained by 
repeating the test after 1 or 2 weeks. The result also needs to be correlated 
with a detailed ultrasonography targeting fetal organogenesis. The 
management protocol that is followed in the IREP is given in Figure 2. 
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Of late, ultrasonography that can detect several fetal malformations 
has become an integral part of antenatal check. Early detection of 
malformations such as spina bifida and meningomyelocele require careful 
ultrasonography by experienced persons. Amniocentesis and cord blood 
analysis may have to be resorted to in selected cases where fetal karyotyping 
also may be required38. 
Vitamin K prophylaxis 
Hemorrhagic disease of the newborn is more likely to occur in infants 
whose mothers are taking hepatic microsomal enzyme-inducing AEDs . A 
dose of 20 mg/day of vitamin K should be given daily orally in the last 
month of pregnancy to these mothers. Infants should receive 1mg of vitamin 
K intramuscularly at birth2,4 . 
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IREP algorithm for follow up during pregnancy : Fig 2 
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Postpartum Management 
The AEDs used in the third trimester should not be continued in the 
first three months postpartum without any alterations in the dosages. Some 
patients would experience exacerbation of seizures during this period, which 
was attributable to sleep deprivation and physical exhaustion. It is helpful to 
arrange with the family members to share some aspects of caring for the 
newborn to avoid undue physical and emotional stress. 
Breast feeding 
Most of the AEDs tend to cross in to the breast milk in inverse 
relation to their protein binding . Newer AEDs tend to pass in to breast milk 
in greater concentration than older drugs.
 
The benefits of breast-feeding 
probably far outweigh the potential risk to the infant. Nevertheless, infants 
need to be carefully monitored for any untoward effects attributable to AED 
exposure through breast milk. Monitoring of infant serum drug 
concentrations is advisable but not mandatory.
 
The general recommendation 
is to continue breastfeeding, but the feeds may be given before the woman 
takes her AED doses4. 
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AMERICAN ACADEMY OF NEUROLOGY 
RECOMMENDATIONS 
 
The American academy of neurology(AAN) has also released 
comprehensive clinical guidelines for the management of women with 
epilepsy during pregnancy. These guidelines first formulated in 1998 are 
now being updated35. 
WWE during reproductive years 
The following recommendations are proposed as guidelines 
• The choice of AED for WWE during their reproductive years should 
be that deemed most appropriate for seizure type. 
• Monotherapy should be the aim of treatment. 
• The decrease in effectiveness of hormonal contraception observed in 
WWE taking enzyme-inducing AEDs must be discussed with all 
WWE as they enter reproductive years. 
• In light of known pregnancy patterns (high rate of unplanned 
pregnancies and late provider contact), folic acid supplementation 
should be instituted in WWE with no less than 0.4 mg per day and 
continued through pregnancy. 
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WWE during and after pregnancy 
 
The following recommendations are proposed as guidelines: 
 
• AED therapy for WWE should be optimized before conception if 
possible. If AED withdrawal is planned, this should be completed at 
least 6 months before conception. Change to an alternate AED should 
not be undertaken during pregnancy for the sole purpose of reducing 
teratogenic risk. 
• WWE, especially those treated with carbamazepine,divalproex 
sodium, or valproic acid, should be offered prenatal testing with 
alpha-fetoprotein levels at 14 to 16 weeks’ gestation, Level I1 
(structural)ultrasound at 16 to 20 weeks’ gestation, and, if appropriate, 
amniocentesis for amniotic fluid alpha-fetoprotein and 
acetylcholinesterase levels. 
• Breast-feeding is not contraindicated in WWE taking AEDs; however, 
for WWE taking sedating AEDs, the neonate must be monitored for 
sedation. 
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The following recommendations are proposed as practice options: 
 
• Non-protein-bound AED levels should be monitored during 
pregnancy. For the stable patient, levels should be ascertained before 
conception, at the beginning of each trimester, and in the last month of 
pregnancy. Additional levels should be done when clinically indicated 
(seizure occurrence, side effects, suspected noncompliance). 
• AED levels should be monitored through the eighth postpartum week. 
If AED dosage increases have been necessary during pregnancy, 
subsequent reductions to the prepregnancy dosage will usually be 
possible and may be necessary to avoid toxicity. 
• Vitamin K, 10 mg per day, should be prescribed in the last month of 
pregnancy to WWE taking enzyme-inducing AEDs. If this has not 
been done, parenteral vitamin K, should be administered toWWE as 
soon as possible after the onset of labor. 
 
Note: This recommendation does not supplant the ACOG/AAP 
recommendation for the administration of 1 mg vitamin K, to the 
neonate. 
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Recommendations for future research 
• There remains a need for well-designed studies of pregnancy 
outcomes for WWE, especially in light of the availability of several 
new AEDs. 
• A study of the efficacy of hormonal contraception in WWE is needed 
in order that those requiring AEDs can be appropriately counseled 
regarding optimal birth control methods. 
• Investigation of the complex issues surrounding seizure frequency 
changes through the stages of reproductive life and with cyclic 
hormonal fluctuations over the menstrual cycle is necessary. 
• Further research into genetic markers that may predict a susceptibility 
to the teratogenic effects of AEDs may help guide primary and 
secondary preventive efforts. 
• Ethical issues surrounding testing of AEDs in women during 
reproductive years must be explored and addressed. 
• Endorsement and promotion of pregnancy registries to monitor AED 
teratogenesis should be undertaken by professional organizations of 
health care providers involved in the care of WWE. 
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MATERIALS AND METHODS 
 
Criteria for patient selection 
• This study includes women with epilepsy already registered at the 
epilepsy clinic of the Government Stanley hospital, Chennai. 
• Patients were included in the study when pregnancy was first 
reported. 
 
Exclusion criteria 
• Patients changing antiepileptic drugs during the course of the study 
were excluded. 
 
Methodology 
This is an observational study involving women with epilepsy 
undergoing regular treatment at the epilepsy clinic of the department of 
neurology of the Government Stanley hospital. It addresses various issues 
faced by epileptic women during and after pregnancy. 
• Pregnant women with epilepsy are included in the study when 
pregnancy is first reported. 
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• Data regarding seizure type, antiepileptic drug used, seizure 
frequency, folate supplementation is collected using a proforma based 
on the EURAP pregnancy registry proforma during the first visit. The 
patient is also counseled about various aspects of pregnancy in 
epileptics. 
• Patient is followed up through monthly visits to the epilepsy clinic. 
Biochemical screening in the form of serum alpha feto protein level is 
done by the 12-14th week of gestation. Ultrasound scan for foetal 
anomalies is done during the 16-18th week of pregnancy. 
• After delivery data is collected regarding outcome, intrapartum 
seizures, mode of delivery using a proforma. The baby is examined 
for growth retardation as well as congenital malformations. 
Maternal serum alpha feto protein 
AFP is a glycoprotein produced first by the yolk sac and then by the 
foetal liver. It reaches its maximum by 10 to 13 weeks of gestation, then 
declines to <100µg/L by term. It is usually reported as multiple of median 
(MoM) to minimize interlaboratory variability and adjust for patients’ 
weight, gestational age and twin pregnancies. It is a valuable screening test 
in various conditions. This study uses this test as an early screen for neural 
tube defects which are known to be associated with antiepileltic drug use37. 
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Levels are increased in 
• Open neural tube defects(detects 80% of severe cases) 
• Ventral wall defects – gastroschisis, omphalocoele 
• Multiple pregnancy 
• Intra uterine death 
• Esophageal or duodenal atresia 
• Cystic hygroma 
• Renal disorders – agenesis, polycystic kidneys, urethral obstruction 
• Turners syndrome 
• Oligohydramnios 
• Placental causes – infarction,thrombosis 
Levels are decreased in 
• Downs syndrome, Edwards syndrome 
• Long standing foetal death 
• Overestimation of gestational age 
• Increased maternal weight, diabetes mellitus 
 
 
 
 40
PROFORMA 
 
A detailed history was recorded as per the following proforma 
• Name: 
• Age : 
• Address: 
• Registration number: 
• Education/occupation: 
• Seizure type: 
• Seizure etiology: 
• Seizure history(pre pregnancy) : Seizure frequency 
AED used and dose 
• Obstretic history: Gravida 
Para 
Abortions 
• LMP: 
• Duration of pregnancy when first reported: 
• EDD: 
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• Spontaneous abortion/MTP:  yes/no 
• Radiation exposure:  yes/no 
• Pregnancy details – therapy 
 AED Dose Folic acid Dose 
1st trimester     
2nd trimester     
3rd trimester     
 
• Pregnancy details – epilepsy 
 Seizure 
frequency 
Status  
epilepticus 
Non convulsive 
seizures 
1st trimester    
2nd trimester    
3rd trimester    
 
• Alpha feto protein level: 
• Structural ultrasound:          Date 
Report 
• Date of delivery: 
• Intra partum seizures:   Yes/No 
• Intra partum status epilepticus:  Yes/No 
• Other complications of pregnancy, specify: 
• Mode of delivery: 
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• Comments reg mode of delivery: 
• Birth weight: 
• Congenital malformations:  Yes/No 
Specify type 
• Perinatal mortality:   Yes/No 
Specify cause 
• Infant mortality:    Yes/No 
Specify cause 
• Developmental milestones: 
 
 
 
 
 
 
 
 
 
 
 43
OBSERVATIONS AND ANALYSIS 
 
This study was conducted in Government Stanley hospital during the 
years 2007-2008. A total of 93 women with epilepsy were enrolled and 
followed up. All patients were already on treatment at the epilepsy clinic at 
the time of inclusion into the study. Patients who changed anti epileptic 
drugs during the course of pregnancy were excluded from the study. 
• Total number of study subjects: 93 
• Age 
The age of the patients ranged from a minimum of 17yrs to a 
maximum of 34yrs. The mean age was 23.75yrs. The age distribution is as 
follows. 
<20 years            -       26 patients 
20 to 25years        -       41 patients 
25 to 30years        -       18 patients 
>30years              -         8 patients 
 44
          
               AGE DISTRIBUTION
20 - 25
44%
25 - 30
19%
>30
9%
<20
28%
<20
20 - 25
25 - 30
>30
 
• Type of epilepsy 
Of the 93 patients in the study, a majority of 67 patients (73%) had 
generalized tonic clonic seizures. 25 patients had partial seizures, either 
simple or complex. 1 patient had juvenile myoclonic epilepsy. 
• Obstetric status 
The study included primigravidas as well as multigravidas. 45 patients 
were primis. 48 patients were multigravidas. 
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• Antiepileptic drug used 
The older antiepileptic drugs mainly – phenytoin, carbamazepine, and 
sodium valproate are the ones being used at the epilepsy clinic of the 
Government Stanley hospital. They are used either singly or in combination. 
Appropriate drugs are given for epilepsy syndromes. But the use of newer 
antiepileptic drugs is rare. The patients in this study were on the following 
drugs- 
Phenytoin(PHT)             -         32 patients (34%) 
Carbamazepine(CBZ)     -        24 patients (25.5%) 
Sodium valproate(SVA)  -        12 patients (12.8%) 
PHT + CBZ                     -          3 patients (3.2%) 
PHT + SVA                     -          2 patients (2.1%) 
CBZ + SVA                     -          5 patients (5.3%) 
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AED'S used
Folic acid supplementation in the first trimester 
Patients who reported pregnancy to the epilepsy clinic were all 
prescribed folic acid tablets. These tablets contained 1mg of folic acid. 
However it was observed that a large number of patients reported their 
pregnancy late and hence did not take folic acid supplementation during the 
first trimester. Another subset of patients had been taking 5mg folic acid 
tablets as prescribed by their Obstetrician. 
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Folic acid (1mg)        -        45 patients 
Folic acid (5mg)        -        13 patients 
No folic acid              -        35 patients 
• Seizures during pregnancy 
The majority of patients had an uneventful seizure free pregnancy. 19 
patients (20.1%) had seizures during the first trimester. 13 patients (13.9%) 
had seizures during the second and third trimesters. It was observed that 
patients with poorly controlled seizures in the preconceptional period 
continued to have seizures even during pregnancy. 
Seizure frequency in the first trimester is as follows: 
Seizure frequency Number of patients Percentage 
No seizures 75 79.8 
< 1/month 7 7.4 
monthly 7 7.4 
weekly 4 4.2 
daily 1 1.1 
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Seizure frequency in the second and third trimester is as follows: 
Seizure frequency Number of patients Percentage 
No seizures 63 67 
<1/month 6 6.4 
Monthly 6 6.4 
Weekly 0 0 
Daily 1 1.1 
 
 
Seizure frequency - 1st trimester
75
7
7 4 1
No
<1/month
monthly
weekly
daily
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Seizure frequency - 2nd trimester
63
6
6 0 1
No
<1/mont
h
monthly
weekly
 
• Incidence of status epilepticus 
2 patients presented with an episode of status epilepticus each in the 
first trimester. 
One patient had generalized tonic clonic seizures and was on 
treatment with phenytoin. She had an increased frequency of seizures in the 
first trimester with 2-3 episodes/week. Seizure frequency decreased in later 
trimesters, she did not have intrapartum seizures. She had a normal vaginal 
delivery and the baby was normal. 
The second patient also had generalized tonic clonic seizures and was 
on phenytoin. She had 3-4 episodes of seizures weekly in the first trimester. 
She had a spontaneous abortion following status. 
Both these patients had poor seizure control preconceptionally. 
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• Intrapartum seizures 
A total of 4 patients had seizures during delivery. The details are as 
follows: 
Sl. 
No 
Seizures 
 in 1st 
trimester 
Seizures 
 in 2nd, 3rd 
trimester 
AED 
used 
Mode of 
delivery 
Comments 
1. No Monthly CBZ Normal Normal baby 
2. Monthly Weekly SVA Operative Normal baby 
3. No Weekly SVA+C
BZ 
Operative Normal baby 
4. No No SVA+C
BZ 
Operative Normal baby 
 
It was observed that incidence of intrapartum seizures was higher in 
patients who reported seizures during the 2nd ,3rd trimesters. Three of these 
patients had an increased seizure frequency in the later part of pregnancy as 
compared to the 1st trimester.  Intrapartum seizures also constituted an 
important indication for operative deliveries as three of the four patients 
ultimately underwent cesarian sections. All these three patients were on 
treatment with valproate. 
 Three of these patients had primary generalized seizures.  One had 
complex partial seizure with secondary generalization. 
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• Incidence of spontaneous abortions 
Spontaneous abortion was observed in 10 patients (10.6%). A 
significant correlation was observed between occurance of seizures in the 
first trimester and increased incidence of spontaneous abortions. 
 
A p value of 0.04 was obtained. 
Spontaneous abortion 
No Yes 
 n % n % 
No 67 80.7% 7 70.0% Seizures 
in 1st 
trimester yes 16 19.3% 3 30.0% 
 
A significant correlation was also observed between spontaneous 
abortions and folate supplementation. 
7 of the 10 patients who had spontaneous abortions had not received 
folate supplementation in the first trimester. 2 had received 1mg of folic acid 
and 1 patient had received 5mg of folic acid. 
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It was observed that of the 35 patients who did not receive folate, 7 
patients – 20% had spontaneous abortions. Of the 45 patients who received 
folate 2 patients – 4.4% had spontaneous abortions. This figure was 1- 7.6%  
among the group of 13 patients on 5mg of folate. 
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• Mode of delivery 
16 out of a total of 64 patients who reached term underwent operative 
deliveries. There is an increased incidence of operative deliveries in women 
with epilepsy as compared to the hospital average for controls. It is 
statistically significant with a p value of 0.04. 
This data is represented in the following table 
 Study control 
Incidence of 
operative delivery 
25% 15% 
sample size 64 10,000 
P = 0.04 
The indication for operative delivery was fetal distress in 2 patients, 
intrapartum seizures in 3 patients, post dated pregnancy in 6 patients, 
malposition in 1 patient and previous LSCS in 2 patients. 
Sodium valproate use was observed to be associated with higher 
incidence of operative deliveries. Of  the 6 patients who were on sodium 
valproate at the time of delivery 5 underwent operative deliveries. All 4 
patients who were on a combination of sodium valproate and carbamazepine 
had operative deliveries. 
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• malformations 
Only one major congenital malformation was seen. The baby had a 
cleft lip and palate(1.6%). The mother had been on monotherapy with 
sodium valproate. She had not been on folic acid supplementation. 
• Low birth weight 
16 out of 64 babies (25%) were low birth weight and weighed under 
2500gm. 
• Perinatal mortality 
1 baby(1.1%) was still born at 36weeks of gestation. Cause was not 
ascertained. 
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DISCUSSION 
 
This study followed 93 pregnancies in women with epilepsy, the 
following observations were made 
Seizures during pregnancy in women with epilepsy 
Of the 93 pregnancies followed, a majority of 74 (79.8%) were 
seizure free throughout. 19 patients (20%) had seizures in the first trimester. 
13 patients (13.9%) had seizures in the second and third trimesters. Factors 
that could have been associated with seizures are poor seizure control even 
before pregnancy, deliberate non compliance with anti epileptic drug intake, 
sleep deprivation and decreased blood levels of anti epileptic drugs during 
pregnancy. 
Similar seizure frequency was seen in a study by Endo.S et al26, who 
reported a seizure frequency of 19.4%. 
A frequency of 30% was seen in a study by Bunyan et al30. 
Another study by Vajda et al23 reported a seizure frequency of 49%. 
Epilepsies that were active in the year before pregnancy tended to have 
increased risk of seizures during pregnancy. 
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Intrapartum seizures 
In this study 4 patients(6.3%) of the 64 patients who reached term 
developed intrapartum seizures. 3 of these patients had primary generalized 
seizures and 1 had complex partial seizure with secondary generalization. 
Intrapartum seizures were not observed in patients with simple partial 
seizures. Correlation was seen between increased seizure frequency in the 
third trimester and intrapartum seizures in 3 patients. Intrapartum seizures 
also observed to lead to increased frequency of operative delivery with 3 of 
our patients requiring caesarian sections. 
Studies by the EURAP study group22 showed an intrapartum seizure 
frequency of 3.5%. Intrapartum seizures were more common in women who 
had seizures during pregnancy. A study by Richmond et al28 also supports 
this observation. 
Katz et al27 reported an intrapartum seizure frequency of 12.5%. All 
of these patients had generalized epilepsies as in our study. 3 out of 4 
patients had subtherapeutic anti epileptic drug levels. 
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Spontaneous abortions 
10 patients (10.6%) had spontaneous abortions. 7 out of these 10 
patients had not received folic acid supplementation. A positive correlation 
was observed between occurrence of seizures in the first trimester and 
spontaneous abortions with a p value of  <0.04. 
Studies by Richmond et al28, Schupf et al32 and Goel et al29 all show 
increased incidence of spontaneous abortion in women with epilepsy. The 
reasons for this observation are – the effect of anti epileptic drug intake, 
effect of seizures on gonadotropin levels. Some studies have also shown an 
association of low folate levels with increased incidence of spontaneous 
abortion. 
Mode of delivery 
This study showed an increased incidence of operative deliveries. 16 
patients (25%) underwent caesarian sections. This was statistically 
significant with a p value of 0.04. There was a positive correlation with anti 
epileptic drug polytherapy, especially with the use of sodium valproate. 
An Indian study by Thomas et al31 showed similar results with a one 
third incidence of operative delivery. A study by Richmond et al28 showed 
no significant increase in operative deliveries, but showed an increase in the 
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number of patients needing induction of labor. Overall most studies show an 
increase in the interventions done during delivery in women with epilepsy. 
Folic acid supplementation 
62% of our patients had received folic acid supplementation. The 
dosage varied from 1 to 5 mg with 59% of patients taking 1mg. This 
compares with the situation in developed countries where 64 t0 78% of 
patients receive folic acid supplementation – Seale et al34. 
An Indian study by Thomas et al 31 reported a 40% use of folic acid. 
Our study also shows an increase in incidence of spontaneous 
abortions in women who have not received folic acid. 
Adverse outcomes of pregnancy in women with epilepsy 
Low birth weight was the commonest adverse outcome seen in our 
study. 25% of neonates were low birth weight. This value is in concordance 
with  the 21% incidence of low birth weight observed by Thomas et al 31. 
An incidence of 18% was observed by Goel et al 29. A Saudi Arabian 
study by Bunyan et al30 showed an incidence of 9%. The incidence in 
developed countries ranges from 7 to 10% - Sivgos et al. 
Economic and social factors also probably contribute to the increased 
incidence seen in our country. 
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Only one major congenital malformation was seen in this study 
(1.6%). One neonate had a cleft lip and palate. The mother was on 
800mg/day of sodium valproate for generalized tonic clonic seizures. She 
had not received folic acid. 
Orofacial clefts constitute 30% of all major congenital malformations 
– Kelly et al.  An Indian study by Goel et al29 with 37 patients reported no 
congenital malformations. On the other hand another Indian study by 
Thomas et al 31 reported an incidence of 12.5%. 
Most studies show the risk of congenital malformations in infants of 
epileptic women to range from 3 to 10% - Tomson et al3. The risk may 
increase to up to 17% with polytherapy – Crawford et al4. 
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CONCLUSION 
 
In a study of 93 pregnancies in women with epilepsy it was found 
that: 
1. A majority of 79.8% were seizure free. 20% had seizures in first 
trimester and this figure diminished to 13.9% later in the course of 
pregnancy. 
2. Intrapartum seizures were seen to be related to: 
a. Seizures in the third trimester 
b. Generalized type of seizure disorder 
c. Increased incidence of operative delivery 
3. An increased incidence of spontaneous abortions was seen in 
women with epilepsy. This was found to correlate with seizures in 
the first trimester and also with a lack of folic acid 
supplementation. 
4. There was an increased incidence of operative deliveries in women 
     with epilepsy. This was associated with polytherapy especially   
     including sodium valproate. 
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5. Only 62% of patients received folic acid supplementation. 
Incidence of  complications like spontaneous abortions were higher 
in patients not receiving folic acid. 
6. Low birth weight is the commonest adverse neonatal outcome. 
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Key to master chart 
A. Name of patient 
B. Surname 
C. Last menstrual period 
D. Age of the patient 
E. Education: Graduate                   1 
                          High school          2 
                          Primary school      3 
                          Illiterate                   4 
F. Radiation exposure during pregnancy 
G. Gravida 
H. Parity 
I. Type of epilepsy: GTCS              1 
                                     Partial              2 
J.   Etiology:               Idiopathic          1 
                                     Symptomatic   2 
K. Spontaneous abortion: No          0 
                                          Yes          1 
L.  Induced termination of pregnancy: No       0 
                                                         Yes     1 
M. Expected date of delivery 
N.  Preg. dur: duration of pregnancy when first reported 
O. Folate supplementation:  No               0 
                                           1 mg          1 
                                            5 mg                2 
P. Anti epileptic drug used in first trimester 
                       Phenytoin                         1 
                       Carbamazepine                 2 
                       Sodium valproate             3 
                       PHT+CBZ                        4 
                       PHT+SVA                        5 
                       SVA+CBZ                        6 
Q. Dose of AED in first trimester 
R. Peak dose of AED 
S. Seizures in the first trimester:   No                          0 
                                                          <1/month               1 
                                                           Monthly                2 
                                                           Weekly                 3 
                                                           >weekly                4,   daily        5 
T. Status epilepticus in first trimester: No                  0 
                                                        Convulsive              1 
                                                        Nonconvulsive        2 
U. Still birth : No       0 
                         Yes     1 
V.AED use in second trimester: No       0 
                                                       Yes      1 
W. Seizures in second trimester 
X. Status epilepticus in second trimester 
Y. Malformation directed ultrasound:  Not done 0 
                                                          Normal           1 
                                                          Abnormal       2 
Z. Alpha feto protein:    Normal           1 
                                    Increased        2 
                                    Decreased      3 
AA. AFP levels in ng/ml 
AB. AED use in third trimester:    No      0 
                                                  Yes     1 
AC. Seizures in the third trimester  
AD. Status epilepticus in third trimester 
AE. Mode of delivery:    Normal vaginal                1 
                                     Forceps/vaccum              2 
                                     LSCS                     3 
AF. Intrapartum seizures:   No               0 
                                         Yes              1 
AG. Birth weight of neonate in grams 
AH. Perinatal death:    No               0 
                                  Yes              1 
AI. Congenital malformations                                   
 
 
